Regenerative medicine is defined (in 2008) as:
we defined “regenerative pharmacology” as “the application of the pharmacological sciences to accelerate, optimize and characterize (either in vitro or in vivo), the development, maturation and function of bioengineered and regenerating tissues”
In addition to that, the authors state that:
More specifically, regenerative pharmacology seeks not only to create a new generation of therapies for improved symptomatic treatment of disease (i.e., fewer side or off-target effects caused by improved mechanisms of action [MOAs], enhanced localization, and cellular and subcellular specificity), but rather to maximally leverage existing multidisciplinary expertise for the development of transformational curative therapies through implementation of the science of pharmacology in the domains of regenerative medicine and tissue engineering.
Although it seems that in regenerative medicine there is quite a push into tissue engeneering, there remains a role for small molecules supporting regenerative processes in our body.
Since some decades knowledge has been accumulating that palmitoylethanolamide can be regarded as a molecule supporting regenerative processes. In this website many examples have been described. PEA has cardioprotective, neuro-regenerative and reno-regenerative and protective properties.
Chapter 1 – Introduction to Regenerative Pharmacology: A Short Primer on the Role of Pharmacological Sciences in Regenerative Medicine 2008, pp. 3-14